Lundbeck Q3 2019 Financial Results

Lundbeck's strategic brands deliver strong double-digit revenue growth 53 NEW 400 CNC MONTHLY 750 Abilify Maintena North America 800 Europe+Int. Markets +24% 600 500 250 0 800 REXULTI 600 400 200 Q3.17 Q3.18 North America Europe+Int. Markets +30% Q3.19 400 200 0 600 300 Trintellix vortioxetine Brintellix 5mg-10mg-20mg tablets vortioxetine North America Europe+Int. Markets Northera™ (droxidopa) capsules 100mg-200mg-300 ng +33% Q3.17 Q3.18 Q3.19 +38% 0 0 Q3.17 Q3.18 Q3.19 Q3.17 Q3.18 Lundbeck Q3.19

View entire presentation